Vancomycin has been the cornerstone of treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections. This review describes new MRSA-active antibiotics that have recently been introduced and highlights emerging resistance.
INTRODUCTION
Vancomycin has been the predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades; however, concerns about its efficacy have led to the increasing use of newer MRSAactive antimicrobials. The purpose of this review is to evaluate recent additions and changes to our armamentarium against MRSA since the last review published in 2011 [1] . Although a number of new agents have been investigated in clinical studies, these have been predominantly in skin and soft tissue infections and pneumonia, and not more invasive infections such as bacteremia and endocarditis.
CHANGING EPIDEMIOLOGY OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS
A number of community-associated MRSA (CA-MRSA) clones have emerged in different geographic locations [2] . These include CC75 S. argenteus found in remote indigenous communities in Australia 
Ceftaroline
Ceftaroline is a cephalosporin with activity against MRSA because of its affinity for penicillin-binding protein 2a (PBP2a) and has been approved for use in acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired pneumonia (CAP) [21, 22] . The FOCUS 1 and 2 licensing studies for CAP specifically excluded patients with risk factors for MRSA pneumonia [23] . Ceftaroline retains excellent activity against methicillin-susceptible S. aureus and MRSA in surveillance specimens collected for the AWARE program [30, 31] . It is also active in vitro against heterogeneous vancomycin-intermediate S. aureus (hVISA), VISA and daptomycin nonsusceptible (DNS) S. aureus [32, 33] , including in endocarditis models, and enhances membrane binding and daptomycin activity in a pharmacokinetic/pharmacodynamic model of DNS VISA [34] . Although adverse effects were infrequent and rates of discontinuation in clinical trials were similar to comparator agents [23,35 & ], off-label use has been associated with similar [27 & ] or increased rates of hematologic
KEY POINTS
Ceftaroline and ceftobiprole are anti-MRSA cephalosporins approved for ABSSSI and pneumonia, and case reports have emerged of eosinophilic pneumonia associated with ceftaroline.
Tedizolid offers once-daily oxazolidinone dosing with greater potency and reduced toxicity.
Dalbavancin and oritavancin are lipoglycopeptides administered once weekly and may be convenient and cost-effective treatments for ABSSSI.
b-Lactams may be combined with vancomycin or daptomycin to improve access to the cell wall or antibiotic binding in the treatment of MRSA infections.
Resistance continues to emerge in anti-MRSA antimicrobials, although there are no data for new agents, such as tedizolid, dalbavancin and oritavancin.
toxicities and rash leading to discontinuation [36] . Case reports of eosinophilic pneumonia when receiving ceftaroline for MRSA pneumonia have also been reported in postmarketing surveillance [29, 37, 38] .
Ceftobiprole
Another anti-MRSA cephalosporin is ceftobiprole. In a randomized controlled trial of patients requiring hospitalization for CAP, it was noninferior to ceftriaxone with or without linezolid [39] . Ceftobiprole was also noninferior to ceftazidime plus linezolid in the treatment of hospital-acquired pneumonia (HAP) but not ventilator-associated pneumonia (VAP) [ [55] . Of note, comparable cure rates were noted in patients with MRSA HAP. A post-hoc analysis of these studies demonstrated lower survival in telavancin-treated patients with moderate-to-severe renal insufficiency (creatinine clearance <50 ml/min) [56] .
The ASSURE study (NCT00062647) was a phase 2 trial of telavancin compared with vancomycin or an antistaphylococcal penicillin for the treatment of uncomplicated S. aureus bacteremia, and this demonstrated similar cure rates between both groups [57 && ]. Adverse events were more frequent in the telavancin group -particularly increases in serum creatinine -although drug discontinuation rates were similar in both treatment groups [57 && ]. Adverse effects include QT prolongation [57 && ,58] and elevations in serum creatinine and thrombocytopenia [55, 58] .
Dalbavancin
Dalbavancin is a teicoplanin-derived lipoglycopeptide with a prolonged half-life up to 8.5 days that facilitates once-weekly dosing [46
In-vitro data demonstrate eight-fold to 16-fold more activity compared with vancomycin and daptomycin for clinically relevant multidrug-resistant Gram positive pathogens including MRSA [60] , with a typical MIC range from 0.03 to 0.12 mg/l or less for S. aureus [60, 61] . Dalbavancin is also active against hVISA, VISA and clinical staphylococcal strains from patients with osteomyelitis [61] .
Although dalbavancin has not been studied in invasive infection, the DISCOVER 1 and 2 studies compared dalbavancin on days 1 and 8 with vancomycin for a minimum of 3 days plus a step-down to oral linezolid to complete 10-14 days of treatment for ABSSSI [62 && ]. These studies enrolled patients with more severe ABSSSI, using the new criteria required by the United States Food and Drug Administration (FDA), and dalbavancin was noninferior to the comparator arm, including the subset of patients with MRSA [ ]. Oritavancin was recently approved by the FDA for treatment of ABSSSI caused by certain susceptible pathogens, including MRSA, and regulatory approval is currently under review in Europe. There are no clinical trials registered for treatment of serious invasive infections; however, in-vitro data support its use in endocarditis and bacteremia, particularly as oritavancin has excellent intracellular bactericidal activity [64] .
EMERGING RESISTANCE
Despite the lure of newer antimicrobials, S. aureus continues to develop reduced susceptibility or resistance to these agents. There are no current reports of resistance to lipoglycopeptides.
Vancomycin
Fortunately, VRSA remains relatively rare; however, there have been recent cases reported from India, Pakistan, Iran, Portugal and Brazil [71] [72] [73] [74] . Most VRSA is due to the acquisition of the vanA resistance operon [75] that confers vancomycin resistance in enterococci. Worryingly, there is now a case report of a VRSA isolate with coexistent resistance to linezolid and streptogramins in the nasal cavity of a healthcare worker in Iran [72] .
Teicoplanin
As with vancomycin, higher teicoplanin MICs have now also been associated with poor clinical outcomes in serious MRSA infections such as bacteremia and pneumonia [76, 77] .
Linezolid
Rates of linezolid resistance have remained relatively low and stable over the past 14 years as demonstrated by the ZAAPS and LEADER surveillance programs [78] [79] [80] . The most frequent cause of resistance involves mutations in the bacterial 23S ribosomal subunit, the binding site for linezolid [78] [79] [80] . Mutations in the 50S L3 and L4 ribosomal proteins have also been described. A plasmid-mediated acquisition of the cfr gene confers a multidrugresistant phenotype to phenicols, lincosamides, oxazolidinones, pleuromutilins and streptogramin A (also known as the PhLOPS A phenotype), including in the USA300 community-associated MRSA clone [81] .
Daptomycin
Genetic changes associated with the development of daptomycin resistance [82 && ] can occur during treatment in patients with deep-seated or high bacterial burden infections [83] , especially in the mprF gene resulting in altered cell membrane charge and daptomycin binding [82 && , 84, 85 & ]. Recommended dosing of daptomycin for bacteremia and endocarditis now exceeds the initial FDA-approved dose of 6 mg/kg [17, 86] . Coresistance to vancomycin and daptomycin can result from mutations in walKR and rpoB, and these mutations can arise during vancomycin treatment failure without daptomycin exposure [82 && ,87-89] . Other changes targeting teichoic acids, phospholipid genes and cell surface charge have been implicated [90] . Interestingly, daptomycin nonsusceptibility was found in hVISA and VISA isolates collected before the introduction of daptomycin in Australia [91] , further demonstrating that nonsusceptibility can emerge even without daptomycin selection pressure.
Ceftaroline
Heteroresistance to ceftaroline has been reported in laboratory isolates of MRSA, hVISA, VISA, DNS and LNS S. aureus [92] . Mutations in PBP2a lead to lower binding affinity, reduced efficacy and higher MICs [93, 94] . A study from Australia has demonstrated ceftaroline nonsusceptibility among multidrugresistant MRSA clinical isolates, particularly in ST239 MRSA (an endemic hospital MRSA clone) [95] .
Rifampicin
Although rifampicin is not a new MRSA-active agent, nor is rifampicin resistance a new phenomenon, it is important to appreciate that single mutations in the rpoB gene, which are commonly encountered in rifampicin-resistant S. aureus, can confer reduced susceptibility to both vancomycin and daptomycin [96, 97] . Mutations in rpoB have also been associated with reduced susceptibility to host antimicrobial peptides and promote persistent infection [97] . Using dual therapy with vancomycin or daptomycin plus rifampicin without additional anti-MRSA agents is not recommended. 
COMBINATION THERAPY

OTHER MANAGEMENT STRATEGIES
Much interest has been placed on the development of a staphylococcal vaccine as an infection prevention strategy. Unfortunately, despite promising in-vitro and early clinical studies, vaccine candidates have not been successful in phase 3 clinical trials [100, 101] . The most recent trial of the isdBcontaining V710 vaccine in patients undergoing cardiothoracic surgery did not show a reduction in S. aureus bacteremia and/or deep sternal wound infections, and was surprisingly associated with increased mortality [102 && ]. Further analysis is under way to explain these findings.
The advent of benchtop next-generation sequencing techniques has allowed more efficient tracking of bacterial isolates in real time, for example, during a clinical outbreak of MRSA in a neonatal unit [103] . Apart from identifying potential transmission pathways or detecting antimicrobial resistance, this approach may also guide empiric therapy during an outbreak on the basis of the in silico antibiogram of identified strains. 46.
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